$430,000 of CME GROUP INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) (Title VII: Wall Street Transparency and Accountability); Issues related to regulation of clearinghouses, swap data repositories, swap execution facilities, and designated contract markets; Issues related to CFTC Funding; Issues related to Derivatives Clearing Market Structure; Issues related to CFTC Reauthorization; H.R. 4763 - Financial Innovation and Technology for the 21st Century Act (118th Congress) (issues related to Sec. 101 - Definitions under the Securities Act of 1933, Sec. 102 - Definitions under the Commodity Exchange Act, Sec. 103 - Definitions under this Act, Sec. 107 - Commodity Exchange Act savings provisions, and Section 401 - Commission jurisdiction over digital commodity transactions); Issues related to the Clearing of US Treasury futures. Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) (Title II: Issues related to orderly liquidation authority and Title VIII: Payment Clearing and Settlement Supervision); Issues related to the regulation of systemically important financial market utilities; Issues related to Crypto Spot Market Regulation; S. 394 - GENIUS Act of 2025; H.R. 2392 - STABLE Act of 2025; Issues related to Basel III Bank Capital Standards; Issues related to the Clearing of US Treasury futures. Issues related to tax treatment of futures, securities, and commodities; Issues related to Sec. 1256 of the tax code related to the tax treatment of futures and options."
You can find more data on corporate lobbying on Quiver Quantitative.
CME Congressional Stock Trading
Members of Congress have traded $CME stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CME stock by members of Congress over the last 6 months:
- REPRESENTATIVE CAROL D. MILLER purchased up to $15,000 on 03/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CME Insider Trading Activity
CME insiders have traded $CME stock on the open market 19 times in the past 6 months. Of those trades, 6 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CME stock by insiders over the last 6 months:
- TERRENCE A DUFFY (Chairman and CEO) sold 30,000 shares for an estimated $7,775,400
- JULIE WINKLER (Sr MD Chief Commercial Officer) sold 11,592 shares for an estimated $2,888,378
- HOWARD J SIEGEL sold 10,000 shares for an estimated $2,600,000
- KEN VROMAN (Chief Transformation Officer) sold 5,066 shares for an estimated $1,266,500
- SUNIL CUTINHO (Chief Information Officer) sold 4,500 shares for an estimated $1,019,878
- HILDA HARRIS PIELL (Sr MD & Chief HR Officer) sold 3,984 shares for an estimated $997,852
- WILLIAM R SHEPARD has made 6 purchases buying 1,979 shares for an estimated $462,075 and 0 sales.
- DEBORAH J LUCAS sold 1,500 shares for an estimated $385,425
- SUZANNE SPRAGUE (COO & Global Head of Clearing) sold 1,500 shares for an estimated $385,249
- TIMOTHY FRANCIS MCCOURT (Sr MD Global Head Equity & FX) sold 1,374 shares for an estimated $312,056
- TIMOTHY S. BITSBERGER has made 0 purchases and 2 sales selling 1,000 shares for an estimated $226,957.
- ELIZABETH A COOK sold 750 shares for an estimated $169,751
- MARTIN J GEPSMAN sold 400 shares for an estimated $89,168
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CME Hedge Fund Activity
We have seen 678 institutional investors add shares of CME stock to their portfolio, and 575 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,921,278 shares (+89.9%) to their portfolio in Q4 2024, for an estimated $910,638,389
- GQG PARTNERS LLC removed 2,044,609 shares (-98.6%) from their portfolio in Q4 2024, for an estimated $474,819,548
- PARNASSUS INVESTMENTS, LLC removed 1,890,660 shares (-83.8%) from their portfolio in Q4 2024, for an estimated $439,067,971
- AMUNDI removed 1,360,003 shares (-38.4%) from their portfolio in Q4 2024, for an estimated $315,833,496
- BALYASNY ASSET MANAGEMENT L.P. removed 1,141,943 shares (-88.8%) from their portfolio in Q4 2024, for an estimated $265,193,422
- CAPITAL WEALTH PLANNING, LLC added 996,498 shares (+69.2%) to their portfolio in Q4 2024, for an estimated $231,416,730
- EGERTON CAPITAL (UK) LLP added 964,421 shares (+inf%) to their portfolio in Q4 2024, for an estimated $223,967,488
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CME Analyst Ratings
Wall Street analysts have issued reports on $CME in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Outperform" rating on 03/10/2025
- Citigroup issued a "Buy" rating on 10/24/2024
To track analyst ratings and price targets for CME, check out Quiver Quantitative's $CME forecast page.
CME Price Targets
Multiple analysts have issued price targets for $CME recently. We have seen 3 analysts offer price targets for $CME in the last 6 months, with a median target of $258.0.
Here are some recent targets:
- Patrick O'Shaughnessy from Raymond James set a target price of $287.0 on 03/10/2025
- Owen Lau from Oppenheimer set a target price of $258.0 on 10/24/2024
- Benjamin Budish from Barclays set a target price of $231.0 on 10/24/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
